---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-043794"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-12-06T23:59:59+00:00"
generated_at: "2026-06-07T16:54:49.682257+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MyMD Pharma gains FDA clearance for Phase 2 trial of oral MYMD-1 in rheumatoid arthritis

## Summary
- FDA cleared IND for Phase 2 trial of oral MYMD-1 (TNF-α inhibitor) in rheumatoid arthritis.
- Trial planned for Q1 2024; will enroll ~60 patients with active RA at 1050 mg oral dose.
- Preclinical data: MYMD-1 reduced disease severity by 47% vs 37% for Enbrel (etanercept).
- MYMD-1 could become first FDA-approved orally administered TNF-α inhibitor for RA.
- RA affects ~1.5M Americans with annual societal cost estimated over $40 billion.

## SEC filing metadata
- accession: 0001493152-23-043794
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223043794/0001493152-23-043794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223043794/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-043794
- JSON: https://secwatch.observer/filing/0001493152-23-043794.json
- Plain text: https://secwatch.observer/filing/0001493152-23-043794.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.